The effect of weight change on kidney cancer patients treated with targeted therapy

A recent retrospective study of 3311 patients with metastatic renal cell carcinoma (RCC) and on first- or second-line targeted therapy clinical trials showed that patients who experience weight loss during treatment have worse outcomes compared with patients with stable weight at 6 and 12 weeks of treatment. Weight loss at 6 weeks after the start of treatment with a targeted therapy might be an early clinical biomarker of worse survival.

Read more in UroToday here

Share this Post!


Related post

  TOP